Adocia Sa · EURONEXT:ADOC
Adocia Sa — Investor Presentation (November 2026)
33 slides from Adocia Sa's investor presentation, November 2026
Slide 1: ADOCIA Presentation
ADOCIA Presentation November 2026 Euronext Paris (ADOC - ADOBSA)
Slide 2: Forward-looking statements
Forward-looking statements ADOC This corporate presentation (the “Presentation”) has been prepared by ADOCIA S.A. (the “Company” and, together with its subsidiary, the “Group”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall m
Slide 3: Innovative peptide delivery technologies for diabetes and obesity
Adocia: innovative peptide delivery technologies for diabetes and obesity Out-licensing platform partnering model following proof-of-concept Ability to tailor the technology to partners' proprietary peptides Lead platform - BioChaperone®: 3 other proprietary platforms – Innovative team with a librar
Slide 4: Executive leadership team with proven track record
Executive leadership team with proven track record Olivier Soula, Mathieu-William You Ping Chan, Martin Gaudier, Jérémy Benattar, PhD, MBA Gilbert PhD, MBA PhD PharmD, Eng CEO & CFO & Head of R&D Head of R&D – Head of Business Co-founder COO - CMC Preclinical & Clinical Development 4 4
Slide 5: Metabolic diseases: a large, fast-growing market primed for innovation
Metabolic diseases: a large, fast-growing market primed for innovation 2025 Global prevalence in adults1-4 By 2050… 2050 prediction 1.95B 1 in 3 adults Obesity 1B will be obese 853M 1 in 8 adults Diabetes 589M will have diabetes $20B $150B insulin market in 20245 GLP-1 receptor agonist market in 203
Slide 6: Diabetes and obesity: significant unmet needs to achieve real health impact
Diabetes and obesity: significant unmet needs to achieve real health impact Current therapies reach too few patients, for a too short time 1% People with Obesity globally treated ~50% of patients discontinue GLP-1 with branded Anti-Obesity Medication3 within the first year in real-world practice1,2
Slide 7: Adocia technologies enabling meaningful Health Impact
Adocia technologies enabling meaningful Health Impact Increase manufacturing capacity BioChaperone® AdoXLong Improve Reduce Expert in patient COGS Peptide experience delivery AdOral® AdoShell® Enable differentiated drug delivery Close the gap between healthspan and lifespan 7 7
Slide 8: A diversified portfolio of specialized products in a rapidly growing market
A diversified portfolio of specialized products in a rapidly growing market, backed by a strong partnership for an asset nearing approval Targeted Platform Program Indication Preclinical Phase 1 Phase 2 Phase 3 Regulatory Status / Upcoming Milestones • Positive Phase 3 results in T2D and T1D BC 222
Slide 9: BioChaperone
BioChaperone® Formulation and co-formulation of peptides 9 9
Slide 10: BioChaperone technology: a toolbox to formulate peptides
BioChaperone® technology: a toolbox to formulate peptides • More than 800 BioChaperone novel proprietary polymer excipients • > 30 positive clinical trials involving BioChaperone • 2 most advanced BioChaperone: BC 449 and BC 222 BC 449 BC 222 • BC CagriSema (GLP-1/ amylin) • BioChaperone® Lispro App
Slide 11: BioChaperone Lispro
BioChaperone® Lispro A novel ultra-rapid insulin improving glycemic control 11 11
Slide 12: BC Lispro: positive Phase 3 trial results vs Humalog in T1D and T2D
BC 222 BC Lispro: positive Phase 3 trial results vs Humalog® in T1D and T2D in China Endpoints Other positive results Primary: Improved postprandial blood glucose control after each meal Non inferior HbA1c reduction at compared to the standard of care 26 weeks Good safety and tolerability Secondary:
Slide 13: BC Lispro: potential to become the best mealtime insulin
BC 222 BC Lispro: potential to become the best mealtime insulin Blood glucose (SMBG), mmol/L, week 26, * p<0.05 ● Humalog® ● BC Lispro 11 T1D 10 * * Phase 3 of 550 people 9 * with T1D randomized with 8 3:2 ratio, 490 completers1 7 Improved glycemic FBG 1h 2h Pre 1h 2h Pre 1h 2h Bed Fasting Breakfast
Slide 14: BC Lispro: strategic partnership with Tonghua Dongbao in China
BC 222 BC Lispro: strategic partnership with Tonghua Dongbao in China Partnered with 78% $2.3B of THDB revenue from THDB market cap3 insulin2 Achieved Next steps Double-digit $10M $5M $10M $20M Royalties Upfront, license 1st patient in Phase 3 Last Positive Phase 3 in Marketing Approval in China Sal
Slide 15: BC Lispro commercial distribution: $7B global prandial insulin market
BC 222 BC Lispro commercial distribution: $7B Global prandial insulin market in 2025 China and other Asian Countries eligible for a EU/US : Regulated markets countries covered by THDB simplified registration requiring a new Phase 3 Main countries Main countries ال إله إال هللا محمد رسول هللا EU US
Slide 16: BioChaperone 449
BioChaperone® 449 Stabilizing and combining peptides 16 16
Slide 17: BioChaperone 449 mechanism of action
BC 449 BioChaperone® 449 mechanism of action In the primary packaging In the subcutaneous compartment BioChaperone® BC biologic non-covalent molecular Dissociation of BC-peptide (Acylated polyglutamate) complexes (electrostatic bonds) complexes due to interaction with plasma proteins (e.g. HSA) At t
Slide 18: BioChaperone offers a unique stabilization effect
BC 449 BioChaperone® offers a unique stabilization effect Technical challenge API(s) Obtained with BioChaperone® Glargine (basal insuline) + Lispro (rapid insulin) Fixed Dose Combination Incompatible Pramlintide (amylin) + Human Insulin combination Glucagon + Exenatide (GLP1) Human Glucagon Ready-to
Slide 19: BioChaperone applied to Amylin/GLP-1: key attributes
BC 449 BioChaperone® applied to Amylin/GLP-1: key attributes 4 auto-injectors 1 multi-use pen / 4 weeks / 4 weeks Amylin BioChaperone® Manufacturing cost GLP-1 Treatment capacity x4 Capital Expenditure Possibility of personalized dosing BioChaperone® is designed to stabilize amylin and GLP-1 i
Slide 20: Expanding the range of potential collaborations with BioChaperone
BC 449 Expanding the range of potential collaborations with BioChaperone® Paid R&D collaboration Licensing agreement Partners test BioChaperone® freely and confidentially Triggered if the partner wishes to conduct an in vivo evaluation Scope: in vitro proof-of-concept Confidentiality, strategic for
Slide 21: BC 449 has been successfully developed as a pharmaceutical excipient
BC 449 BC 449 has been successfully developed as a pharmaceutical excipient Easy to manufacture and easily scalable • Patented amphiphilic polymer up to 2038 • Fully soluble and stable (>2 years at 2-8°C) • Available at a GMP-grade on 20-kg scale with scale-up plan reaching 3T by 2030 A safe excipie
Slide 22: AdoXLong
AdoXLong Long-acting peptides compatible with once-monthly injections 22 22
Slide 23: AdoXLong platform: extending half-life of peptides for once-monthly injection
AdoXLong AdoXLong platform: extending half-life of peptides for once-monthly injection Biocompatible polymer covalently linked to the peptide ADOXLONG ➔ Increased half-life PLATFORM ➔ Standard manufacturing process ➔ Patent filed in Nov. 2025, all peptides could be protected till 2046 • Clear aqueou
Slide 24: AdoXLong platform: potential for once-a-month exposure in humans
AdoXLong AdoXLong platform: potential for once-a-month exposure in humans PK profile after single SC administration to rats PK profile after administration in farm pigs AdoXL Sema, SC, 60 nmol/kg Semaglutide simulation, SC, 60 nmol/kg PK data in pigs will be presented T1/2 = 32h at Obesity Week 2026
Slide 25: AdoShell
AdoShell® Peptide-secreting cells delivery without immunosuppression 25 25
Slide 26: AdoShell: addressing islets transplantation challenges in T1D
AdoShell® AdoShell®: addressing islets transplantation challenges in T1D Unmet needs with insulin Toward a cure for T1D: AdoShell® platform: replacement therapies Unmet needs with islets transplantation cell encapsulation + scaffold Primary Islet Transplantation Allow insulin secretion in • ≈10 M pe
Slide 27: AdoShell: permselective hydrogel for cell therapy without immunosuppression
AdoShell® AdoShell®: permselective hydrogel for cell therapy without immunosuppression Pancreatic islets OR Stem cells Immuno-isolation from donors derived islets Ab, T cells Large entities >10nm AdoShell® Minimally surgery (laparoscopy) Free diffusion Biomaterial (hydrogel + reinforcing frame) Oxyg
Slide 28: In vivo proof-of-concept of AdoShell with human islets and SCDI
AdoShell® In vivo proof-of-concept of AdoShell® with human islets and SCDI Functionality and efficacy of AdoShell® Functionality and efficacy of with human islets AdoShell® with SCDI Xenogeneic transplantation of Transplantation of AdoShell® SC-islets AdoShell® human islets in NXG mice in NXG mice A
Slide 29: AdoShell: successful scale-up from animal to human device
AdoShell® AdoShell®: successful scale-up from animal to human device for first-in-human study Human size AdoShell® prototype Simple implantation procedure by minimally- surgery (laparoscopy) Laparoscopic Placement and Fixation with introduction* unrolling in the site tackers Roll-up cm 11 3 cm 15 cm
Slide 30: AdoShell: ready for the clinic
AdoShell® AdoShell®: ready for the clinic TODAY T1D Cure Immuno protection Human islets Regulatory studies ongoing Function and efficacy FIH Stem cells derived islets Looking for partners Surgical procedure Other cell therapies applications Stem cells PoC with hepatic SC: Looking for partners FIH in
Slide 31: Upcoming inflexion points
Upcoming inflexion points 31 31
Slide 32: One product ready for market, one technology ready for late development and 2 technologies for clinics
One product ready for market, one technology ready for late development and 2 technologies for clinics Phase 3 & licensing Ambition to Ambition to Market-ready ready go to clinic go to clinic BioChaperone® Lispro BioChaperone® AdoXLong AdoShell® Partnership with Tonghua BC 449 AdoXL Sema Technology
Slide 33: Thank you for your kind interest
Thank you for your kind interest 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 contact@adocia.com